Qilu Pharmaceutical Advances First-in-Class Bispecific Antibody QLS2312 Targeting APRIL and MASP-2 into Phase I Clinical Trial for IgA Nephropathy

Recently, Qilu Pharmaceutical'sQLS2312Injection inClinicalTrials.govquietly registered a Phase I clinical trial.

70healthy subjects, estimated2027Year11Completed in [Month]. The figures are modest, but the drug’s target combination warrants attention:APRIL and MASP-2: An Uncharted Bispecific Antibody Pathway

To understand this design, one must go back toIgAThe “Four-Hit” Theory of Kidney Disease.

Aberrant GlycosylationIgA1After being produced in the mucosa, the molecules enter the bloodstream, triggering the formation of autoantibodies and immune complexes that deposit in the glomeruli, ultimately activating the complement system and leading to inflammation and fibrosis.

APRILIt is precisely the driver of pathogenicityIgA1generated upstream switch, andMASP-2is the initiating enzyme of the complement lectin pathway; Qilu’s bispecific antibody design effectively “sets up checkpoints” simultaneously at both the upstream and downstream segments of the pathological cascade.

Each of the two pathways has its own story. Otsuka'sAPRILAntibodySibeprenlimabApproved in the United States, Phase IIIVISIONARYStudies have shown that it can stabilize the rate of decline in renal function to an age-related range.

AndMASP-2The path is much more tortuous:OmerosofNarsoplimabPhase II data were impressive, yet Phase III failed to meet the primary endpoint.IgADevelopment of renal indications was forced to terminate, ultimately shifting toTA-TMAfirst to cross the finish line.

Same Target, Different Fates: This Precisely Illustrates That the Single-Target Strategy inIgANot a panacea in kidney disease.

The Chinese market has an especially urgent need for this answer.

IgANephropathy accounts for primary glomerulonephritis in China30%Above, the patient approximately500ten thousand people, with over new confirmed cases annually1010,000 cases.

More importantly, over the past two years, globally there have already been6FundIgANew Kidney Disease Drug Approved, Telitacicept,AtaciceptAs dual-target drugs successively hit the market, the therapeutic landscape is rapidly shifting from “no available treatments” to a “multi-target competition.”

Qilu Pharmaceutical has previously hadsiRNAMedicationQLS7305LayoutIgAKidney Disease, Now RevisitedAPRIL/MASP-2Bispecific antibodies, forming "small nucleic acid+Bispecific antibody pipeline portfolio.

Of course, the druggability challenge of bispecific antibodies far exceeds that of monoclonal antibodies.

The affinity ratio between the two arms, the risk of infection associated with complement inhibition, and whether the synergistic effect of dual-targeting can be truly realized are all questions that must be answered in Phase I clinical trials.

MASP-2The setbacks of single-target therapies serve as a cautionary tale; whether Qilu Pharmaceutical can tell a different story with its “combination punch” depends not on design blueprints, but on future clinical data.